Update on medications with adverse skeletal effects

Mayo Clin Proc. 2011 Apr;86(4):338-43; quiz 343. doi: 10.4065/mcp.2010.0636. Epub 2011 Mar 9.

Abstract

Patients rely on their primary care physician to manage multiple, often chronic medical conditions that require prescription medications. Balancing the risk to benefit of treatments can be challenging and requires that the primary care physician stay abreast of new information regarding risks and benefits. The number of medications with reported adverse effects on skeletal health is expanding. This review focuses on medications recently added to the list of "bad to the bone" drugs and on recent advances in management of glucocorticoid-induced osteoporosis. A practical approach to assessing and managing the skeletal risks is outlined.

Publication types

  • Review

MeSH terms

  • Animals
  • Aromatase Inhibitors / adverse effects
  • Aromatase Inhibitors / therapeutic use
  • Bone Density / drug effects
  • Bone and Bones / drug effects*
  • Breast Neoplasms / drug therapy
  • Contraceptive Agents, Female / adverse effects
  • Diphosphonates / therapeutic use
  • Fractures, Bone / chemically induced
  • Glucocorticoids / adverse effects
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Medroxyprogesterone Acetate / adverse effects
  • Osteoporosis / chemically induced*
  • Osteoporosis / drug therapy
  • Peroxisome Proliferator-Activated Receptors / agonists
  • Proton Pump Inhibitors / therapeutic use
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / therapeutic use

Substances

  • Aromatase Inhibitors
  • Contraceptive Agents, Female
  • Diphosphonates
  • Glucocorticoids
  • Peroxisome Proliferator-Activated Receptors
  • Proton Pump Inhibitors
  • Serotonin Uptake Inhibitors
  • Thiazolidinediones
  • Gonadotropin-Releasing Hormone
  • Medroxyprogesterone Acetate